CYSTO-CONRAY II SOLUTION

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

IOTHALAMATE MEGLUMINE

Disponible desde:

LIEBEL-FLARSHEIM COMPANY LLC

Código ATC:

V08AA04

Designación común internacional (DCI):

IOTALAMIC ACID

Dosis:

172MG

formulario farmacéutico:

SOLUTION

Composición:

IOTHALAMATE MEGLUMINE 172MG

Vía de administración:

URETHRAL

Unidades en paquete:

250/500ML

tipo de receta:

Ethical

Área terapéutica:

ROENTGENOGRAPHY

Resumen del producto:

Active ingredient group (AIG) number: 0102763004; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2021-12-02

Ficha técnica

_ _
_Page 1 of 14_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
CYSTO-CONRAY
® II
Iothalamate Meglumine Injection USP
17.2 % w/v
Solution
IONIC IODINATED RADIOGRAPHIC CONTRAST MEDIUM FOR INSTILLATION OF THE
URINARY TRACT.
Liebel-Flarsheim Company LLC Date of Revision:
8800 Durant Road November 26, 2021
Raleigh, North Carolina
27616 USA
Importer:
Liebel-Flarsheim Canada Inc.
7500 Trans-Canada Highway
Pointe-Claire, Quebec
H9R 5H8
Submission Control No.: 255550
_ _
_ _
_Page 2 of 14_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................5
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
............................................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
PART II: SCIENTIFIC INFORMATION
...............................................................................10
PHARMACEUTICAL INFORMATION
..........................................................................10
DETAILED PHARMACOLOGY
.....................................................................................10
REFER